Testing a cream for irritative contact dermatitis
Testing the Effectiveness of an Intervention in Irritative Contact Dermatitis:Randomized Controlled Trial
This study tests whether an omega cream can help people with skin irritation from a common chemical to see if it reduces redness, blisters, dryness, and itching.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Sex | All |
| Sponsor | University of Split, School of Medicine Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Split) |
| Trial ID | NCT06189144 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of an omega cream in treating irritative contact dermatitis induced by sodium lauryl sulfate (SLS). It focuses on the inflammatory response of the skin, which can manifest as erythema, blistering, dryness, and itchiness. Healthy volunteers will be enrolled to assess the cream's impact compared to a no-treatment control group. Participants will be monitored for skin reactions and overall improvement in symptoms.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy volunteers without any significant skin conditions or recent use of certain medications.
Not a fit: Patients with skin cancer, significant skin diseases, or those who have used corticosteroids or other specified medications recently may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could provide a new topical treatment option for patients suffering from irritative contact dermatitis.
How similar studies have performed: While there have been studies on topical treatments for dermatitis, the specific use of omega cream in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * healthy volunteers who gave written informed consent Exclusion Criteria: * · skin cancer * skin disease * skin damage on measurement sites * use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial * use of drugs that may cause photosensitivity * use of emollients three days prior the inclusion in the trial * non-adherence to the trial protocol * exposure to artificial and excessive natural ultraviolet (UV) radiation * pregnancy and lactation * history of vitiligo, melasma and other pigmentation and photosensitivity disorders * immunosuppression * allergic or irritant reactions to the constituents of the cream
Where this trial is running
Split
- School of Medicine — Split, Croatia (Recruiting)
Study contacts
- Study coordinator: Josipa Bukic
- Email: jbukic@mefst.hr
- Phone: 00385917933752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.